PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info

9	ubstitute for form 14	AOA (DTO			STATE OF THE OFFI CHIESS IS CONTAINED A VAIID ON TO CONTROL TUMBE		
(abstitute for form 14	49A/P10			Complete if Known		
				Application Number	10/568,765	·	
	INFORMATION DISCLOSURE		Filing Date	February 21, 2006			
S	STATEMEN	NT BY A	PPLICANT	First Named Inventor	Long Dang et al.		
				Art Unit	1651		
	(Use as m	any sheets as	necessary)	Examiner Name	TBD		
Sh	neet 1	of	1	Attorney Docket Number	001107.00591		

			U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					r iguros Appear

		FOREIGN	N PATENT DOCU	MENTS		
Examiner	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 2003/045131	06-05-2003	Spampinato	, <u>, , , , , , , , , , , , , , , , , , </u>	
		WO 2005/039491	05-06-2005	Long		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		D. LONG ET AL., "Combination Bacteriolytic Therapy for the Treatment of Experimental Tumors," Proceedings of the National Academy of Sciences of USA, December18, 2001; Vol. 98, No. 26, pp. 15155-15160	
		J. THEYS ET AL., "Improvement of Clostridium Tumor Targeting Vectors Evaluated in Rat Rhabdomyosarcomas," FEMS Immunology and Medical Microbiology, February 1, 2001, Vol. 30, No. 1, pp. 37-41	
		N.P. MINTON ET AL., "Clostridia in Cancer Therapy," Clostridia Biotechnology and Medical Applications, February 15, 2001, pp. 251-270	
		T. FOJO ET AL., "Taxol and Other Microtubule-Interactive Agents," Current Opinion in Oncologic, Endocrine and Metabolicinvestigational Drugs, January 1, 2001, Vol. 2, No. 3, pp. 293-304	
		R. F. SERVICE, "Chemical Synthesis: Tumor-Killer Made: How Does it Work?" Science, December 20, 1996, Vol. 274, No. 5295, pp. 2009	
		F. VALERIOTE ET AL., "Synergistic Interaction of Anticancer Agents: A Cellular Perspective," Cancer Chemotherapy Reports, September 1, 1975, Vol. 59, No. 5, pp. 895-900	
		D. LONG ET AL., "Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents," Cancer Biology & Therapy, March 2004, Vol. 3, No. 3, pp. 326-337	

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Policy of the Emperor must be document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. The indication of the document by Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.